AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23786367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV) - victim only
Number of subjects: 1044
Study 23786367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV) - perpetrator only
Number of subjects: 1044
Study 23786367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV) - reciprocal violence
Number of subjects: 1044
Study 23786367 — intervention group
Group type: COMPARATOR
Intervention: No intimate partner violence (IPV)
Number of subjects: 1044
Study 23786367 — intervention group
Group type: EXPERIMENTAL
Intervention: Any type of IPV
Number of subjects: 1044
Study 23786367 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal violence
Number of subjects: 1044
Study 23786367 — intervention group
Group type: EXPERIMENTAL
Intervention: Victims of IPV
Number of subjects: 1044
Study 21768314 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 full doses (0.5 mL) of trivalent inactivated influenza vaccine (TIV)
Number of subjects: 252
Study 21768314 — intervention group
Group type: COMPARATOR
Intervention: 2 half doses (0.25 mL) of trivalent inactivated influenza vaccine (TIV)
Number of subjects: 252
Study 19649267 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 3547
Study 19649267 — intervention group
Group type: COMPARATOR
Intervention: Comparator drugs (MAS3, artemether-lumefantrine, amodiaquine+sulfadoxine-pyrimethamine, artesunate+amodiaquine)
Number of subjects: 3547
Study 18029950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal drug delivery systems (IDDSs)
Number of subjects: 0
Study 15724519 — intervention group
Group type: EXPERIMENTAL
Intervention: Monaurally fitted with a linear, programmable hearing aid providing over 20-dB insertion gain at 2000-4000 Hz
Number of subjects: 32
Study 11834959 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use with clients
Number of subjects: 1330
Study 11834959 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevalence
Number of subjects: 1330
Study 11834959 — intervention group
Group type: EXPERIMENTAL
Intervention: Syphilis prevalence
Number of subjects: 1330
Study 11834959 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonorrhoea prevalence
Number of subjects: 1330
Study 11834959 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia prevalence
Number of subjects: 1330
Study 9428842 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 2.0 micrograms.kg‐1.min‐1 (Group 1, n = 10)
Number of subjects: 17
Study 9428842 — intervention group
Group type: COMPARATOR
Intervention: Perfusion pressure > 70 mm Hg during CPB (Group 2, n = 7)
Number of subjects: 17
Study 9428842 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 2.0 micrograms.kg‐1.min‐1 (Group 1)
Number of subjects: 17
Study 9428842 — intervention group
Group type: COMPARATOR
Intervention: Perfusion pressure > 70 mm Hg during CPB (Group 2)
Number of subjects: 17
Study 7647223 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWHs)
Number of subjects: 0
Study 7647223 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study 7647223 — intervention group
Group type: COMPARATOR
Intervention: Sequential compression devices (SCD)
Number of subjects: 0
Study 2729166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate
Number of subjects: 0
Study 2729166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous succinate
Number of subjects: 0
Study 2729166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous saccharate (10% Fe)
Number of subjects: 0
Study 2729166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate
Number of subjects: 0
Study 2729166 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate
Number of subjects: 0
Study 870369 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine and a low copper diet
Number of subjects: 46
Study 870369 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 46
Study 870369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 31283365 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 40
Study 31283365 — intervention group
Group type: COMPARATOR
Intervention: Sham Yoga (Control)
Number of subjects: 40
Study 28656801 — intervention group
Group type: EXPERIMENTAL
Intervention: Malingering for the purpose of receiving stimulant medication
Number of subjects: 167
Study 28656801 — intervention group
Group type: EXPERIMENTAL
Intervention: Malingering for the purpose of receiving extra time accommodations
Number of subjects: 167
Study 28656801 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 167
Study 28656801 — intervention group
Group type: COMPARATOR
Intervention: Individuals with ADHD
Number of subjects: 167
Study 28143840 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention targeting physicians and pharmacist assistants, including a 2-day training workshop, educational outreach visits at 3, 6, and 9 months, an app for decision aid, and a web-based platform for SMS messages to patients.
Number of subjects: 350
Study 28143840 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 350
Study 24451696 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching group (SG, n = 12)
Number of subjects: 24
Study 24451696 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 24
Study 22544676 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC) for 15 minutes
Number of subjects: 50
Study 22544676 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 21526889 — intervention group
Group type: EXPERIMENTAL
Intervention: LRPT 40 mg co-administered with clopidogrel 75 mg
Number of subjects: 0
Study 21526889 — intervention group
Group type: EXPERIMENTAL
Intervention: LRPT 40 mg co-administered with aspirin 81 mg
Number of subjects: 0
Study 21526889 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg alone
Number of subjects: 0
Study 21526889 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 81 mg alone
Number of subjects: 0
Study 17602789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 40 g/day administered at two main meals for 30 days (beer)
Number of subjects: 40
Study 16519142 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdeletion detection using multiplex PCR
Number of subjects: 67
Study 16519142 — intervention group
Group type: COMPARATOR
Intervention: Control group (no microdeletion)
Number of subjects: 67
Study 12918862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical mobilization (contralateral lateral glide technique)
Number of subjects: 20
Study 12918862 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 20
Study 10969672 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intraaortic balloon pump therapy
Number of subjects: 112
Study 10969672 — intervention group
Group type: COMPARATOR
Intervention: High-risk coronary artery bypass graft without preoperative intraaortic balloon pump therapy
Number of subjects: 112
Study 10969672 — intervention group
Group type: COMPARATOR
Intervention: Low-risk coronary artery bypass graft operations
Number of subjects: 112
Study 9080162 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraflo II heparin-coated circuits
Number of subjects: 151
Study 9080162 — intervention group
Group type: COMPARATOR
Intervention: Uncoated circuits
Number of subjects: 151
Study 9080162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 151
Study 7504387 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml.kg-1 LMW-HES (Mw 120,000)
Number of subjects: 45
Study 7504387 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml.kg-1 HMW-HES (Mw 400,000)
Number of subjects: 45
Study 7504387 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate 2000 ml
Number of subjects: 45
Study 3531957 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation treatment directed to the leakage site, using spot sizes of 200 mu in diameter, exposure times of 0.2 seconds, and low‐power intensities.
Number of subjects: 0
Study 29318424 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 60 mg long-acting release
Number of subjects: 34
Study 29318424 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9 %)
Number of subjects: 34
Study 26792419 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine to maintain MAP at pre-anaesthesia levels
Number of subjects: 24
Study 26792419 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving vasopressor if MAP decreased below 60 mmHg
Number of subjects: 24
Study 25471989 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated ankle strengthening
Number of subjects: 120
Study 25471989 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional balance training
Number of subjects: 120
Study 25471989 — intervention group
Group type: COMPARATOR
Intervention: Activity-matched control
Number of subjects: 120
Study 25471989 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 23208763 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental growth factor (PlGF) at visit 1
Number of subjects: 772
Study 21553161 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson (400-μg bolus injection)
Number of subjects: 2015
Study 21553161 — intervention group
Group type: COMPARATOR
Intervention: Adenosine (6-minute infusion)
Number of subjects: 2015
Study 18373605 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 0
Study 18373605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18373605 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 0
Study 16986154 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including feedback, education, alcohol-based hand wash, and visual reminders
Number of subjects: 0
Study 16986154 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback
Number of subjects: 0
Study 16986154 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study 12743984 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine 1000 mg/m2 and vinorelbine 20 mg/m2 on days 1, 8, and 15 of each 28-day cycle
Number of subjects: 30
Study 12743984 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine and vinorelbine
Number of subjects: 30
Study 10892276 — intervention group
Group type: EXPERIMENTAL
Intervention: Adatocel (methylhydroxypropylcellulose)
Number of subjects: 150
Study 10892276 — intervention group
Group type: EXPERIMENTAL
Intervention: Amvisc Plus (sodium hyaluronate)
Number of subjects: 150
Study 10892276 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon (sodium hyaluronate)
Number of subjects: 150
Study 8881952 — intervention group
Group type: EXPERIMENTAL
Intervention: Free PSA in patients with localized CaP (median 8.8%)
Number of subjects: 145
Study 8881952 — intervention group
Group type: EXPERIMENTAL
Intervention: Free PSA in patients with metastatic CaP (median 7.1%)
Number of subjects: 145
Study 8881952 — intervention group
Group type: COMPARATOR
Intervention: Free PSA in patients with BPH (median 19.5%)
Number of subjects: 145
Study 8881952 — intervention group
Group type: COMPARATOR
Intervention: Free PSA in patients with urolithiasis (median 18.8%)
Number of subjects: 145
Study 1356311 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol 100 mg two times a day
Number of subjects: 21
Study 1356311 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol 200 mg two times a day
Number of subjects: 21
Study 1356311 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 240 mg once a day
Number of subjects: 21
Study 1356311 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 1356311 — intervention group
Group type: EXPERIMENTAL
Intervention: all active treatments
Number of subjects: 21
Study 2826563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber (15 g daily for 4 weeks)
Number of subjects: 0
Study 2826563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29122620 — intervention group
Group type: EXPERIMENTAL
Intervention: Convective RF thermal therapy with Rezūm System
Number of subjects: 197
Study 29122620 — intervention group
Group type: COMPARATOR
Intervention: Control (rigid cystoscopy with simulated active treatment sound effects)
Number of subjects: 197
Study 28404067 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infiltration with bupivacaine plus patient-controlled analgesia with morphine
Number of subjects: 105
Study 28404067 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia with bupivacaine and sufentanil
Number of subjects: 105
Study 24861192 — intervention group
Group type: EXPERIMENTAL
Intervention: Decubitus position with 10 mg of 0.5% bupivacaine
Number of subjects: 80
Study 24861192 — intervention group
Group type: COMPARATOR
Intervention: Sitting position with 10 mg of 0.5% bupivacaine
Number of subjects: 80
Study 24861192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Decubitus and Sitting)
Number of subjects: 80
Study 22574801 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive Memory Training (COMET)
Number of subjects: 77
Study 22574801 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 77
Study 20550533 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily for 36 weeks
Number of subjects: 112
Study 20550533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 18431674 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast dissolving films containing TC-Poloxamer 407
Number of subjects: 0
Study 18431674 — intervention group
Group type: EXPERIMENTAL
Intervention: Eugenol containing films
Number of subjects: 0
Study 18431674 — intervention group
Group type: COMPARATOR
Intervention: Fast dissolving films containing TC-HPBCD complex
Number of subjects: 0
Study 16390890 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (100-400 mg/day)
Number of subjects: 145
Study 16390890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 16390890 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 145
Study 16390890 — intervention group
Group type: COMPARATOR
Intervention: DHEA and Placebo
Number of subjects: 145
Study 12728743 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily administration of quetiapine (400 or 600 mg)
Number of subjects: 21
Study 12728743 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily administration of quetiapine (400 or 600 mg)
Number of subjects: 21
Study 12728743 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily administration of quetiapine
Number of subjects: 21
Study 12728743 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily administration of quetiapine
Number of subjects: 21
Study 9890410 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure oxygen administration for 30 min
Number of subjects: 35
Study 9890410 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure oxygen administration for 30 min with right atrial pacing in 12 patients
Number of subjects: 35
Study 7484891 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (Group A)
Number of subjects: 434
Study 7484891 — intervention group
Group type: COMPARATOR
Intervention: No thrombolysis (Group B)
Number of subjects: 434
Study 2076623 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen gel (10%)
Number of subjects: 100
Study 2076623 — intervention group
Group type: COMPARATOR
Intervention: Flufenamic acid gel (3%)
Number of subjects: 100
Study 375088 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 113
Study 375088 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine
Number of subjects: 113
Study 31359460 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 140
Study 31359460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 140
Study 28885314 — intervention group
Group type: EXPERIMENTAL
Intervention: SADBE
Number of subjects: 36
Study 28885314 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 36
Study 28885314 — intervention group
Group type: EXPERIMENTAL
Intervention: SADBE (after switching from vehicle)
Number of subjects: 36
Study 25733777 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-like dietary counseling
Number of subjects: 563
Study 25733777 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (2.4 g/d)
Number of subjects: 563
Study 25733777 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 563
Study 25733777 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 563
Study 23802816 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin
Number of subjects: 13686
Study 23802816 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 13686
Study 21668387 — intervention group
Group type: EXPERIMENTAL
Intervention: ABG‐I stem
Number of subjects: 100
Study 21668387 — intervention group
Group type: EXPERIMENTAL
Intervention: Unique customized femoral stem
Number of subjects: 100
Study 19192976 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 10/160 mg
Number of subjects: 947
Study 19192976 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 5/160 mg
Number of subjects: 947
Study 19192976 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 947
Study 16723303 — intervention group
Group type: EXPERIMENTAL
Intervention: HT25 (0.025 mg/day)
Number of subjects: 66
Study 16723303 — intervention group
Group type: EXPERIMENTAL
Intervention: HT50 (0.050 mg/day)
Number of subjects: 66
Study 15523323 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose enalapril
Number of subjects: 74
Study 15523323 — intervention group
Group type: COMPARATOR
Intervention: Low-dose enalapril
Number of subjects: 74
Study 11421866 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 375
Study 11421866 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 375
Study 11421866 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg
Number of subjects: 375
Study 11421866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 9024100 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized estradiol, 1.0 mg
Number of subjects: 87
Study 9024100 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens, 0.625 mg
Number of subjects: 87
Study 9024100 — intervention group
Group type: COMPARATOR
Intervention: Micronized estradiol, 0.5 mg
Number of subjects: 87
Study 8328566 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release alprazolam (highest mean dose = 4.7 mg/day)
Number of subjects: 194
Study 8328566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 8328566 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release alprazolam
Number of subjects: 194
Study 3819670 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Medicine Clinic
Number of subjects: 520
Study 3819670 — intervention group
Group type: COMPARATOR
Intervention: Family Practice Clinic
Number of subjects: 520
Study 30525929 — intervention group
Group type: EXPERIMENTAL
Intervention: Global signal regression (GSR)
Number of subjects: 0
Study 26330286 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care model
Number of subjects: 56
Study 26330286 — intervention group
Group type: COMPARATOR
Intervention: Hospital outpatient clinics
Number of subjects: 56
Study 24696051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 55
Study 24696051 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 55
Study 23530786 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1 mg/kg alone (Group P)
Number of subjects: 39
Study 23530786 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg and remifentanil 1 µg/kg (Group R)
Number of subjects: 39
Study 23530786 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane alone 6% (Group S)
Number of subjects: 39
Study 20610555 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg/kg
Number of subjects: 109
Study 20610555 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 100 microg/kg
Number of subjects: 109
Study 20610555 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 microg/kg
Number of subjects: 109
Study 20610555 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 50 microg/kg
Number of subjects: 109
Study 20610555 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 109
Study 20610555 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 109
Study 18077795 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 4731
Study 18077795 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorrhagic stroke as entry event
Number of subjects: 4731
Study 18077795 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 4731
Study 18077795 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (10 year increments)
Number of subjects: 4731
Study 18077795 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 2 hypertension at last visit
Number of subjects: 4731
Study 16606391 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic template
Number of subjects: 193
Study 16606391 — intervention group
Group type: COMPARATOR
Intervention: Manual template
Number of subjects: 193
Study 16606391 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet detection of VT
Number of subjects: 193
Study 12720620 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation (200 ml sweet or salty sip feed twice daily, providing 500 kcal, 21 g protein per day)
Number of subjects: 80
Study 12720620 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral supplementation)
Number of subjects: 80
Study 12720620 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation
Number of subjects: 80